Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q8N3Y3

UPID:
LARG2_HUMAN

ALTERNATIVE NAMES:
Glycosyltransferase-like 1B; LARGE xylosyl- and glucuronyltransferase 2

ALTERNATIVE UPACC:
Q8N3Y3; A6NN75; Q8N8Y6; Q8NAK3; Q8WY62

BACKGROUND:
The protein Xylosyl- and glucuronyltransferase LARGE2, with alternative names Glycosyltransferase-like 1B and LARGE xylosyl- and glucuronyltransferase 2, is instrumental in glycosylation processes. It significantly supports the maturation of alpha-dystroglycan, a critical component for cell-matrix interactions, by adding repeating units of xylose and glucuronic acid. This activity not only aids in the production of a heteropolysaccharide but also modifies proteoglycans to enhance laminin binding, underscoring its multifaceted biological role.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Xylosyl- and glucuronyltransferase LARGE2 could open doors to potential therapeutic strategies.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.